The 1917 Clinic conducts research trials on new drugs and treatments for HIV/AIDS and associated conditions. These clinical trials study the benefits and risks of new treatments that may stop HIV's destruction of the immune system.

Clinical research also looks at treatments to prevent or cure various opportunistic infections, complications/side effects of HIV therapy as well as ways to rebuild damaged immune systems.

By participating in a clinical research trial you have :

  • The chance to receive an experimental medicine or treatment before it is widely available.
  • The opportunity to receive regular medical attention and other services at little or no cost.
  • The satisfaction of contributing to scientific knowledge about the diseases and improving existing treatments.

To find out about the various eligibility requirements to participate in a research trial, ask your Physician, Nurse, or Social Worker or contact :

Pamela Cunningham, Program Director
pamelacunningham@uabmc.edu

Click below to view our upcoming and currently enrolling research studies. 
 

Industry Studies

Anticipated Start: Summer 2019

Bavarian Nordic RSV is anticipated to be a Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of the Recobinant MVA-BN RSV vaccine after intranasal and intramuscular administration. RSV: Respiratory Syncytical Virus

Eligibility criteria has not yet been determined and will be updated as received.

If interested in placement on the wait-list for this study, please contact us via phone or the web.

Anticipated Start: June 2019

A randomized, double-blind, multicenter Phase III trial to evaluate immunogenicity and safety of three consecutive production lots of a freeze-dried formulation of MVA-BN smallpox vaccine in healthy, vaccinia-naive subjects.

If interested in placement on the wait-list for this study, please contact us via phone or the web.


Prevention Studies



The Flu Vaccine study is a Phase II study assessing safety, reactogenicity, and immunogenicity of a Sanofi Pasteur A/H7N9 inactivated Influenza vaccine administered intramuscularly with or without AS03 adjuvant.

This study is open to healthy, HIV-negative adults aged 19 to 64 years old. Females able to become pregnant must be willing to use a medically accepted contraceptive method from 30 days before first vaccination until 60 days after the last study vaccination. Participation in this study will last approximately 13 months with up to 8 scheduled clinic visits and 2-7 phone calls depending on which group you are randomized into.

Other inclusion criteria applies. Compensation is provided after enrollment for those who qualify. This study will enroll rapidly over a 12 week period once open. If interested in participating, it is recommended that you contact us immediately to be placed on the wait-list for eligibility screening.

For more information or to be placed on the wait-list for this study, please contact us via phone or the web.
    
 

HVTN 121 is a Phase Ib open label clinical trial to evaluate HIV-1 neutralization on antibody breadth in response to HIV gp120 protein vaccine in HIV-uninfected adults with quiescent Systemic Lupus Erthematosus.

For more information or to be placed on the wait-list for this study, please contact us via phone or the web.


 
            

Microbicide Studies

MTN 035 is a Phase I study.
 

Researchers are interested in developing a rectal product to protect against HIV infection during anal sex. This study is being done to see what kinds of products people would prefer to use before anal sex— a douche, an insert, or a suppository. Participants will be asked to use each product for a period of 1 month and complete surveys about their opinion and experiences with each one. There is no active drug in any of the products being used. The study lasts about 3 months, and involves a total of 8 visits. You will be compensated for your time.

.
 
MTN 037 is a Phase I study.

The purpose of the study is to test the safety and acceptability of a new rectal gel, which is being developed to protect against HIV infection during anal sex.  If you are HIV negative and have had anal sex at least once in your life, you may be eligible to participate. The study involves 9 visits over a period of about 3-5 months. During this time, participants will insert the gel, rectally, a total of 3 times. Rectal biopsies will be collected at 5 of the visits. You will be compensated for your time.